Skip to main content
Fig. 3 | BMC Infectious Diseases

Fig. 3

From: Phase 2 randomised placebo-controlled trial of spironolactone and dexamethasone versus dexamethasone in COVID-19 hospitalised patients in Delhi

Fig. 3

Primary Biomarker Outcomes. Day 1, 4 and 7 measurement of patient blood biomarkers (a) D-dimer, (b) VWF, (c) aldosterone and (d) angiotensin II. Mean and s.e.m shown. Analysed by two-way ANOVA, p < 0.05 indicated within the figure. For all, patient number (n) included in analysis is shown below the plot, Dex: squares, orange; SpiroDex: circles, blue

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us